Earnings call transcript: Teraplast posts mixed H1 2026 results as Q2 rebounds

Teraplast’s H1 2026 revenue rose 4% to RON 574m, but EBITDA fell 9% to RON 42.5m and the company swung to a RON 4m net loss, largely reflecting higher personnel costs, FX losses, and higher interest expense. While Q2 improved materially (standalone revenue +12% to RON 339m and standalone EBITDA +30% to RON 34m), leverage increased to 4.8x (from 4.0x) with bank loans rising to RON 446m. The company is also expanding, completing a ~EUR 3.7m Spain factory purchase (Okondo, via Aliaxis), with consolidation starting Q3, but shares were described as little changed near the lower end of the 52-week range.

Analysis

The key market read-through is not the revenue line; it is that pricing is doing the heavy lifting while volumes remain soft. That usually signals a late-cycle or post-shock environment where input costs can be passed through for a quarter or two, but end-demand is not yet healthy enough to support durable margin expansion. The combination of higher leverage, FX drag, and rising interest expense makes equity value more sensitive than usual to small misses in operating cash flow; in this setup, a 1-2 turn move in debt/EBITDA can dominate the narrative more than a modest EBITDA beat.

The packaging segment is the cleanest temporary winner, but the market should treat it as a cyclical spike rather than a new structural margin regime. If geopolitical demand normalizes and raw-material availability stabilizes, that segment’s earnings power likely mean-reverts faster than consensus expects, which could leave the group with a less profitable mix just as the larger installation and compounds businesses are still working through weak volumes. The Spain asset adds geographic optionality, but near term it is primarily a cash and execution story: integration, working-capital drag, and potentially longer payback than the market may be modeling.

The contrarian view is that the stock may already be pricing in too much bad news from the weak first quarter and too little of the Q2 operating inflection. The real catalyst path is H2 volume recovery in Hungary and the compound business; if that does not show up by the next print, the current rerating case breaks. Falsifiers are straightforward: continued negative volume growth, leverage above ~5x, or another round of RON weakness/interest expense pressure that wipes out the gross-margin improvement.

Key Decisions for Investors

• No immediate long exposure: wait for the next quarterly update to confirm that Q2 was not a one-off margin recovery before adding risk to CEE building-materials / plastics processors.
• Use any rally toward the upper end of the recent range to reduce exposure; the cleaner short thesis is still balance-sheet sensitivity plus earnings quality risk, not outright top-line collapse.
• Watch for a reversal in the compound and installation volumes over the next 1-2 quarters; if volumes do not inflect, treat the packaging strength as transitory and reassess the equity as a leverage story rather than a growth story.
• If local liquidity allows, favor a relative-value stance: long the higher-quality regional packaging exposure versus this name, since this company’s upside is more dependent on macro stabilization and integration execution.